



MSN Laboratories Private Limited
R&D Center. Formulation Division.

SAFETY DATA SHEET

Product Name	Olmesartan Medoxomil and Hydrochlorothiazide Tablets 20 mg/ 12.5 mg, 40 mg /12.5 mg and 40 mg / 25 mg/Olmesartan Medoxomil and Hydrochlorothiazide 20 mg /12.5 mg, 40 mg / 12.5 mg and 40 mg / 25 mg Film Coated Tablets	Page 1 of 6
---------------------	---	--------------------

1. Product Information

Product Name: Olmesartan Medoxomil and Hydrochlorothiazide Tablets 20 mg/ 12.5 mg, 40 mg / 12.5 mg and 40 mg / 25 mg/Olmesartan Medoxomil and Hydrochlorothiazide 20 mg / 12.5 mg, 40 mg / 12.5 mg and 40 mg / 25 mg Film Coated Tablets

Chemical Family: Mixture

Intended use: Pharmaceutical product is Anti- hypertensive

MSN Laboratories Private Limited.

Formulation Division, Unit - II,

Sy No 1277 & 1319 to 1324

Nandigama Village & Mandal

Ranga Reddy Dist

Telangana State, India.

PIN 509228

Phone: +918548699000

2. Hazards Identification

Handling should only be performed by personnel trained and familiar with handling of potent active pharmaceutical ingredients Moderate to severe irritant to the skin and eyes.

3. Composition/Information on Ingredients

Olmesartan Medoxomil:

C.A.S. No: : 144689-63-4

Molecular Formula : $C_{29}H_{30}N_6O_6$

Molecular Weight : 558.59

Chemical Name : (2,3-dihydroxy-2-butenyl 4 (1-hydroxy-1-methylethyl)-2-propyl-1-[p-(0-1H-tetrazol-5-ylphenyl)benzyl]imidazole5-carboxylate,cyclic 2,3-carbonate.

Hydrochlorothiazide:

C.A.S. No: : 58-93-5

Molecular Formula : $C_7H_8ClN_3O_4S_2$

Molecular Weight : 297.74

Chemical Name : 6-chloro-1,1-dioxo-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide.

4. First Aid Measures

Eye Contact: Check for and remove contact lenses and flush with copious amounts of water; assure adequate flushing by separating the eyelids with fingers; call a physician.



MSN Laboratories Private Limited
R&D Center. Formulation Division.

SAFETY DATA SHEET

Product Name	Olmesartan Medoxomil and Hydrochlorothiazide Tablets 20 mg/ 12.5 mg, 40 mg /12.5 mg and 40 mg / 25 mg/Olmesartan Medoxomil and Hydrochlorothiazide 20 mg /12.5 mg, 40 mg / 12.5 mg and 40 mg / 25 mg Film Coated Tablets	Page 2 of 6
---------------------	---	--------------------

Skin Contact: flush with copious amounts of water; remove contaminated clothing and shoes; call a physician.

Ingestion: If swallowed, wash out mouth with copious amounts of water; call a physician.

Inhalation: If inhaled, remove to fresh air; if breathing is difficult, give oxygen; if breathing stops, give artificial respiration.

5. Fire Fighting Measures

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Carbon monoxide, carbon dioxide, oxides of nitrogen, oxides of sulfur, hydrochloride, and other chlorine-containing compounds

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

Fire / Explosion Hazards: Not applicable

6. Accidental Release Measures

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment. Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Measures for Environmental Protections:

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Additional Consideration for Large Spills:

Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

FDQA CONTROLLED COPY



MSN Laboratories Private Limited
R&D Center. Formulation Division.

SAFETY DATA SHEET

Product Name	Olmesartan Medoxomil and Hydrochlorothiazide Tablets 20 mg/ 12.5 mg, 40 mg /12.5 mg and 40 mg / 25 mg/Olmesartan Medoxomil and Hydrochlorothiazide 20 mg /12.5 mg, 40 mg / 12.5 mg and 40 mg / 25 mg Film Coated Tablets	Page 3 of 6
---------------------	---	--------------------

7. Handling and Storage

General Handling: Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Refer to Section 12 - Ecological Information, for information on potential effects on the environment. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls. Releases to the environment should be avoided.

Storage Conditions: Store at 20-25 °C (68-77 °F) {see USP controlled Room Temperature}.

8. Exposure Controls/Personal Protection

Environmental Exposure Controls: Refer to specific Member State legislation for requirements under Community environmental legislation.

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes: Wear safety glasses or goggles if eye contact is possible.

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. Physical and Chemical Properties

Appearance:

20/12.5 mg: Light Orange, Round, film-coated, Biconvex tablets, debossed with "MO" on one side and "8" on other side, free from physical defects

40/12.5 mg: Light Orange, Oval, film-coated, Biconvex tablets, debossed with "MO" on one side and "9" on other side, free from physical defects

40/25 mg: Pink, Oval, film-coated, Biconvex tablets, debossed with "MO" on one side and "10" on other side, free from physical defects

FDQA CONTROLLED COPY



MSN Laboratories Private Limited
R&D Center. Formulation Division.

SAFETY DATA SHEET

Product Name	Olmesartan Medoxomil and Hydrochlorothiazide Tablets 20 mg/ 12.5 mg, 40 mg /12.5 mg and 40 mg / 25 mg/Olmesartan Medoxomil and Hydrochlorothiazide 20 mg /12.5 mg, 40 mg / 12.5 mg and 40 mg / 25 mg Film Coated Tablets	Page 4 of 6
---------------------	---	--------------------

10. Stability and Reactivity

Stability	: Stable under normal conditions of use.
Conditions to Avoid	: Fine particles (such as dust and mists) may fuel fires/explosions
Incompatible Materials	: As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products	: None known

11. Toxicological Information

Acute toxicity	: No data available
Skin corrosion/irritation	: No data available
Serious eye damage/eye irritation	: No data available
Respiratory or skin sensitization	: No data available
Germ cell mutagenicity	: No data available
Reproductive toxicity	: No data available
Teratogenicity	: No data available
Specific target organ toxicity single exposure (GHS)	: No data available
Specific target organ toxicity -- repeated exposure (GHS)	: No data available
Aspiration hazard	: No data available
Potential Health Effects	
Inhalation	: May be harmful if inhaled. May cause respiratory tract irritation.
Skin	: May be harmful if absorbed through skin. May cause skin irritation
Eyes	: May cause eye irritation.
Ingestion	: May be harmful if swallowed.
Signs and Symptoms of Exposure	: To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.
Synergistic effects	: No data available
Additional information	: RTECS: Not available

FDQA CONTROLLED COPY



MSN Laboratories Private Limited
R&D Center. Formulation Division.

SAFETY DATA SHEET

Product Name	Olmesartan Medoxomil and Hydrochlorothiazide Tablets 20 mg/ 12.5 mg, 40 mg /12.5 mg and 40 mg / 25 mg/Olmesartan Medoxomil and Hydrochlorothiazide 20 mg /12.5 mg, 40 mg / 12.5 mg and 40 mg / 25 mg Film Coated Tablets	Page 5 of 6
---------------------	---	--------------------

12. Ecological Information

Persistence and degradability : No data available
Toxicity : No data available
Bioaccumulative potential : No data available
Mobility in soil : No data available
PBT and vPvB assessment : No data available
Other adverse effects : No data available

13. Disposal Considerations

Product: Dispose of in accordance with local authority regulations

Contaminated packaging: Packs that cannot be cleaned should be disposed of in the same manner as the contents. Uncontaminated packaging can be recycled.

14. Transport Information

Department of Transportation (DOT) Classification:

UN Number : Not Regulated
UN Shipping name : Not available
Transport hazard class : Not available
Packing group : Not available
Environmental hazard : None
Transport in bulk : Not available
Special precautions : Always transport in closed containers that are upright and secure. Ensure
needed with transport that persons transporting the product know what to do in the event of an
accident or spillage

15. Regulatory Information

OSHA Hazards : No known OSHA hazards

SARA 302 Components : SARA 302: No chemical in this material are subject to the reporting requirements of SARA-Title-111, Section-302

FDQA CONTROLLED COPY



MSN Laboratories Private Limited
R&D Center, Formulation Division.

SAFETY DATA SHEET

Product Name	Olmesartan Medoxomil and Hydrochlorothiazide Tablets 20 mg/ 12.5 mg, 40 mg /12.5 mg and 40 mg / 25 mg/Olmesartan Medoxomil and Hydrochlorothiazide 20 mg /12.5 mg, 40 mg / 12.5 mg and 40 mg / 25 mg Film Coated Tablets	Page 6 of 6
---------------------	---	--------------------

- SARA 313 Components : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title II, Section 313.
- SARA 311/312 Hazards : NO SARA Hazards
- Massachusetts Right To Know Components : No components are subject to the Massachusetts Right to Know Act.
- Pennsylvania Right To Know Components : No components are subject to the Pennsylvania Right to Know Act.
- New Jersey Right To Know Components : No components are subject to the New Jersey Right to Know Act.
- California Prop. 65 Components : This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other reproductive harm.

16. Other Information

While the information herein is believed to be reliable, it is furnished without warranty of any kind. It shall be used only as a guide. We assume no liabilities from the use of this product or information contained herein.

FDQA CONTROLLED COPY